← Back to Search

Corticosteroid

Monotherapy TH-302 Dose Escalation for Multiple Myeloma

Phase 1 & 2
Waitlist Available
Research Sponsored by Threshold Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This phase 2 study is designed to evaluate the safety and tolerability activity of TH-302 and dexamethasone with or without bortezomib or pomalidomide in subjects with relapsed/refractory multiple myeloma.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events (AEs)
Severity of adverse events(AEs)
Type of adverse events(AEs)
+2 more
Secondary outcome measures
Duration of Response (DOR)
Maximum plasma concentration of TH-302 and bortezomib
Overall Survival (OS)
+2 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: TH-302 and Dexamethasone Dose ExpansionExperimental Treatment1 Intervention
Group II: TH-302 Dose Escalation and Dexamethasone with PomalidomideExperimental Treatment1 Intervention
Group III: TH-302 Dose Escalation and Dexamethasone with BortezomibExperimental Treatment1 Intervention
Group IV: Monotherapy TH-302 Dose EscalationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Evofosfamide
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Threshold PharmaceuticalsLead Sponsor
32 Previous Clinical Trials
3,767 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
2012. "Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01522872.
All > Myeloma > Velcade
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top